1 / 49

DRUGS AFFECTING THE RESPIRATORY ORGANS FUNCTION

DRUGS AFFECTING THE RESPIRATORY ORGANS FUNCTION. Drugs affecting the respiratory organs function anticough drugs ; expectorants ; breathing stimulants ; drugs used for bronchial asthma ; drugs used for lungs edema. REHYDRANTS IN ALL CASES. Anticough drugs.

july
Download Presentation

DRUGS AFFECTING THE RESPIRATORY ORGANS FUNCTION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. DRUGS AFFECTING THE RESPIRATORY ORGANS FUNCTION

  2. Drugs affecting the respiratory organsfunction • anticough drugs; • expectorants; • breathing stimulants; • drugs used for bronchial asthma; • drugs used for lungs edema

  3. REHYDRANTS IN ALL CASES

  4. Anticough drugs • Drugs of central action (depress central links of cough reflex): • а)narcotic:codein, dextromethorphan • б) nonnarcotic:glaucin hydrochloride (glauvent), oxeladin citrate (tussuprex) • Drugs of peripheral action (block sensitivereceptors of cough reflexogenic zones): libexin

  5. Oxeladin citrate, Tussuprex

  6. Glaucin hydrochloride (glauvent) + ephedrine + Sage oil

  7. Libexin

  8. Expectorants • Secrete-motor drugs (stimulate expectoration): • а) drugs of reflex action: drugs of medical plants, sodium benzoate, bronchicum elixir, mucaltin • б) drugs of resorbtive and local action: bromide -sodium and potassium, ammonium chloride, sodium hydrocarbonate, ether oils • Bronchosecretolytic drugs (mucolytics): • а) proteolytic enzymes: tripsin, chimopsin, chimotripsin, desoxyribonuclease • б) mucolytics: acetylcystein, carbocystein • в) drugs which influence surfactant production or surfactants: bromhexin, ambroxol, “Alveofakt”, “Ekzosurf”

  9. Drugs of medical plants Althea officinalis Thermopsis Viola

  10. Combined remedy “Bronchicum”

  11. Mucaltin (Mucaltinum)

  12. Drugs of medical plants Ledum palustrae Origanum vulgaris

  13. Crystal tripsin (Trуpsinum crystallisatum) Ampoules - 0,005 gand 0,01 g

  14. Acetylcystein (Acetylcysteinum) Forms of production:tablets - 0,1, 0,2 and 0,6, 20 % solution for inhalation in ampoules – 5 and 10 ml; 10 % solution for injection in ampoules - 2 ml and 5 % solution in ampoules – 10ml.

  15. Bromhexin (Bromhexinum)

  16. Аmbroxol (Lasolvan) Forms of production: tablets - 0,03 and syrup.

  17. COUGHDry With presence of sputum in bronchi • PRODUCTIVE Sputum with significant viscous-elastic properties-muco- and proteolytic drugs Sputum with significant adhesive properties-drugs which stimulate production of surfactant Decreasing of speed of mucociliar transport with unchanged properties of sputum- drugs which stimulate cilia function Significant disorders of bronchial permeability, morphological changes ofbronchi (atrophy of mucous membrane, bronchial stenosis), excessive production of mucus-alkali inhalations Signs of allergic reaction with increased histamine activity -antihistamine drugs • NONPRODUCTIVE Cataral inflammation (usually viral), reflector and central cough -anticough drugs Signs of allergic reaction -antihistamine drugs Bronchospasm -broncholytics REHYDRANTS IN ALL CASES

  18. Stimulants of breathing (analeptics) • Analeptics of direct action: bemegrid, ethymisol, caffeine • Analeptics of mixed action: cordiamin, camphor, carbon acid (carbogen – mixture of O2 and CO2) • Analeptics of reflex action: lobelin, cytiton

  19. Aethimizol (Aethimizolum) Sodium caffeine-benzoate (Coffeinum-natrii benzoas) Bemegrid (Bemegridum)

  20. Cordiamin (Cordiaminum) Camphor (Camphora)

  21. DRUGS FOR BRONCHIAL ASTHMA

  22. Introduction • Chronic inflammatory disease of the airways • Most common childhood chronic disease • Affects ~4.8 million (CDC, 1995) • >100 million days of restricted activity • 470,000 hospitalizations/yr

  23. Introduction • >5000 deaths annually • Highest in blacks ages 15-24 • Hospitalizations highest in blacks & children

  24. Pathogenesis and Definition • Key points • Chronic inflammatory disorder of the airways • Immunohistopathologic features • denudation of airway epithelium • collagen deposition beneath basement membrane • edema • mast cell activation

  25. Working definition of asthma (1995, NHLBI) • Asthma is a chronic inflammatory disorder of the airways in which many cells & cellular elements play a role (mast cells, eosinophils, T lymphocytes, macrophages, neutrophils, & epithelial cells).

  26. Airflow limitation • Acute bronchoconstriction • stress - mechanisms ?? • Airway edema • mediators • increase microvascular permeability/ leakage • mucosal thickening & airway swelling • airway rigidity

  27. To remove attack of bronchial asthma • Broncholytic drugs: • Adrenomimetics (α,β-adremonimetics, β-adrenomimetics, β2-adrenomimetics) • Methylxantines • Cholinoblockers (M-cholinoblockers, ganglionblockers) • Antiallergics and drugs that reduce airway hyperresponsiveness • Expectorants

  28. Beta-adrenomimetics Salbutamol, Ventolin,Berotek,Asthmopent

  29. Asthma Treatment/Quick Relief • Short-acting beta2 agonists • Relax airway smooth muscle and increase in airflow in <30 minutes • Drug of choice for treating symptoms and exacerbations and EIB • Use of >1 canister/mo indicates inadequate control and indicates need to intensify anti-inflammatory tx • Regularly scheduled use NOT recommended

  30. Long-acting beta-2 agonists • Relax airway smooth muscle • Duration of action >12 hrs • Not used in acute exacerbations • Adjunct to anti-inflammatory tx for long-term symptom control especially nocturnal symptoms

  31. Methylxanthines Theophyllin(of prolonged action)

  32. Methylxanthines • Provides mild-moderate bronchodilation • Low dose has mild anti-inflammatory action • Sustained release form used as alternative but not preferred to long-acting beta2 agonists to control nocturnal symptoms • Use may be necessary because of cost or patient compliance

  33. M-cholinoblockers Atropine sulfate, Solutan, Ipratropii bromidum (Atrovent)

  34. Anticholinergics • Cholinergic innervation important in regulation of airway smooth muscle tone • Ipratropium bromide (quaternary derivative of atropine without its’ side effects) • Additive benefit with inhaled beta 2-agonists in severe asthma exacerbations • Effectiveness in long-term management not demonstrated

  35. Inhibitors of mast cells degranulation • Cromolyn, Ketotifen and Nedocromil antagonize antigen-induced (IgE-mediated) mast cell degranulation • they prevent the release of histamine and slow-reacting substance of anaphylaxis (SRS-A) - mediators of type I allergic reactions • their beneficial effects in the treatment of asthma are largely prophylactic

  36. Cromolyn & nedocromil • Have distinctive properties • Similar anti-inflammatory reactions • blocks Cl - channels • modulate mast cell mediator release • modulate eosinophilic recruitment • inhibits early and late asthmatic response to antigen challenge

  37. Cromolyn & nedocromil • Similar anti-inflammatory reactions • inhibits bronchospasm (exercise, cold dry air, bradykinin aerosol) • nedocromil more potent in inhibiting bronchospasm in the above situations • Both reduce asthma symptoms • improve PF • reduce need for short acting beta2 agonists

  38. Cromolyn & nedocromil • Dosing requirements • recommended for both 4 X/day • nedocromil effective at 2 X/day • Clinical response for both is less predictable than steroids • Both have strong safety profile

  39. Ketotifen Tilade (sodium nedocromil)

  40. Corticosteroid hormones in the management of asthma • In 1991- guidelines for the diagnosis and management of asthma were published by the National Asthma Education Program (USA). This report described the patho-physiology of asthma including airway obstruction, airway inflammation, and airway hyperresponsiveness. • Since then, corticosteroids have moved to the forefront in the treatment of asthma.

  41. Corticosteroids • Dose dependent on product and delivery device • 2 X/day use is common in moderate-to-severe persistent asthma • 1 or 2 X/day may be used in mild persistent asthma

  42. Inhaled corticosteroids • Beclomethasone • Budesonide • Dexamethasone • Flunisolide • Fluticasone • Triamcinolone Administration corticosteroids by inhalation limits the systemic adverse reactions associated with oral or parenteral therapy

  43. Administration of inhaled corticosteroids • by the use of chambers or spacers • these devices help decrease systemic absorption and subsequent adverse reactions of the corticosteroids • most inhaled therapy is delivered via metered dose inhalers • other method - the breath-actuated dry powder inhaler devices (Rotahaler, Diskhaler, Turbuhaler)

  44. Prednisolon, Hydrocortizone, Dexamethazone.

  45. Leukotriene modifiers • Leukotrienes are potent biochemical mediators released from mast cells, eosinophils, and basophils that: • contract bronchial smooth muscle • increase vascular permeability • increase mucus secretions • attract & activate inflammatory cells in airways

  46. Potential role in the treatment of asthma • Zileuton - a 5-lipoxygenase inhibitor • Zafirlukast • a leukotriene-receptor antagonist Leukotrienes attract cellular infiltrates producing epithelial injury, abnormalities in neural mechanisms, increases in airway smooth muscle responsiveness, and airway obstruction

  47. Leukotriene modifiers • Zafirlukast & zileuton (oral tabs) • improves lung fx and diminishes symptoms & need for short-acting beta2 agonists • Studies in mild-moderate asthma showing modest improvements • Alternative to low-dose inhaled steroids for pts. with mild persistent asthma • Further study in of other groups needed

  48. Leukotriene modifiers • Zafirlukast - leuktriene receptor antagonist • attenuates late response to inhaled allergen and post-allergen induced bronchospasm • modest improvement in FEV1 (11% > placebo) • improved symptoms • reduced albuterol use • Warning - increases warfarin half-life and PT & PTT must be monitored with dose adjustment when indicated

More Related